AI-generated analysis. Always verify with the original filing.
VivoSim Labs, Inc. (Nasdaq: VIVS) is a pharmaceutical and biotechnology services company focused on providing drug testing in three-dimensional (3D) human tissue models of liver and intestine. The company offers partners toxicology insights using new approach methodologies (NAM) and is advancing a preclinical IBD program. The company has a history of substantial losses, reporting an accumulated deficit of $350.2 million as of December 31, 2025, and a net loss of $2.7 million for the three months ended December 31, 2025. This S-1 filing registers a best-efforts public offering of up to $4.0 million, structured in two tranches ($3.0 million initial and $1.0 million conditional), involving shares of common stock, pre-funded warrants, and common warrants. The company intends to use the net proceeds for working capital and general corporate purposes. The filing highlights a going concern warning, noting that current cash is insufficient to fund operations beyond July 2026 without this capital raise.
Offering Amount
$19.3M
Shares Offered
200,000,000
Price Range
$1.69 – $1.69
Shares Offered
2,366,862
Offering Amount
$4,000,000
Share Type
Common Stock
Exchange
Nasdaq Capital Market
Ticker
VIVS
Use of Proceeds: Working capital and general corporate purposes, including capital expenditures, research and development, and regulatory affairs.
A pharmaceutical and biotechnology services company focused on providing testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine.